Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Apoptotic markers (P53, Bcl-2 and Bax) expression in renal oncocytoma and chromophobe renal cell carcinoma (CROSBI ID 214959)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Demirović, Alma ; Ulamec, Monika ; Bezjak, Miran ; Belicza, Mladen ; Krušlin, Božo Apoptotic markers (P53, Bcl-2 and Bax) expression in renal oncocytoma and chromophobe renal cell carcinoma // Periodicum biologorum, 116 (2014), 2; 173-176

Podaci o odgovornosti

Demirović, Alma ; Ulamec, Monika ; Bezjak, Miran ; Belicza, Mladen ; Krušlin, Božo

engleski

Apoptotic markers (P53, Bcl-2 and Bax) expression in renal oncocytoma and chromophobe renal cell carcinoma

Background and Purpose: Renal oncocytoma (RO) and eosinophilic variant of chromophobe renal cell carcinoma (ChRCC) have overlapping morphologic, immunohistochemical, histochemical and ultrastructural features. Their distinction is mandatory since RO is a benign tumor, while ChRCC is a low-grade malignant tumor which has metastatic potential and may undergo sarcomatoid transformation. The aim of this study was to determine expression of P53, Bcl-2 and Bax in ROs and ChRCCs and to explore whether these markers could be useful in differential diagnosis of RO and ChRCC. Patients and Methods: We analyzed 61 cases (28 ChRCCs and 33 ROs) by immunohistochemistry using primary antibodies to P53, Bcl-2 and Bax. The staining percentage and staining intensity scores were multiplied to give immunohistochemical staining index (ISI). Results and Conclusion: All specimens showed positive reaction for Bcl-2 and Bax. There was no significant difference in the ISI for Bcl-2 and P53. Statistical analysis showed significant difference in the ISI of Bax between ROs and ChRCCs. Moreover, cases of ROs had cytoplasmic pattern of reaction for Bax, while the pattern of reaction for Bax in cases of ChRCCs was membranous. Further studies are needed to confirm the possible use of Bax immunostaining in differential diagnosis of RO and ChRCC.

Renal oncocytoma; chromophobe renal cell carcinoma

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

116 (2)

2014.

173-176

objavljeno

0031-5362

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Indeksiranost